Cervical Cancer Gap Will Widen without Urgent Global Action

Why It Matters

The gap threatens millions of preventable deaths and undermines global health equity, while meeting WHO goals offers a cost‑effective path to save lives and close the disparity.

Key Takeaways

• LMIC cervical cancer incidence could fall 23% by 2105 under current trends
• Raising girls' vaccination to 90% cuts LMIC‑HIC gap to two‑fold
• WHO targets plus multi‑cohort vaccination could avert 37 million cases
• Inequalities may spike seven‑fold by 2065 before benefits appear
• Screening coverage remains under 10% in LMICs versus 84% in HICs

Pulse Analysis

The burden of cervical cancer remains heavily skewed toward low‑and middle‑income countries, which account for more than 80% of the 600,000 new cases diagnosed each year. Limited access to screening—just 10% of women in these regions are tested compared with 84% in high‑income nations—means cancers are caught late, driving a six‑fold higher mortality rate. HPV vaccination, the single most effective preventive tool, is also lagging: only 23% of adolescent girls in LMICs received the series in 2023 versus 57% in wealthier countries. As vaccine prices fall and single‑dose regimens prove effective, the gap is technically bridgeable, yet financing and supply constraints persist.

The Lancet‑published modelling study evaluated 67 LMICs and 42 HICs under a range of interventions. Maintaining the status quo yields a modest 23% decline in LMIC incidence by 2105, while high‑income nations could meet the WHO elimination threshold (<4 cases per 100,000) by 2048. Scaling girls’ coverage to 90% narrows the incidence gap from three‑fold to roughly two‑fold, but full equality requires the WHO’s 90‑70‑90 targets combined with universal, multi‑cohort vaccination. This hybrid strategy could avert up to 37 million cases and compress the HIC‑LMIC lead time to just 20 years.

Policymakers must translate these projections into coordinated action. International donors and vaccine manufacturers should lock in low‑cost, single‑dose supplies to accelerate rollout, while national health ministries need to integrate HPV vaccination with existing adolescent health platforms and expand community‑based screening. The economic case is compelling: preventing millions of cancers reduces treatment costs and preserves productive years for women, directly contributing to broader development goals. Without such urgency, the model predicts a seven‑fold surge in inequality by 2065, underscoring that inaction will cost far more than the investment required today.